Pakistan

Population 2018  212 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>562 (399–754)</td>
<td>265 (188–355)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>3.8 (2.5–5.4)</td>
<td>1.8 (1.2–2.5)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>28 (18–40)</td>
<td>13 (8.4–19)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>43 (35–52)</td>
<td>20 (16–25)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>1.3 (0.83–1.8)</td>
<td>0.6 (0.39–0.86)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases 4.2% (3.2–5.3)
- Previously treated cases 16% (15–17)

TB case notifications, 2018
- Total new and relapse 360 472
  - % tested with rapid diagnostics at time of diagnosis 22%
  - % with known HIV status 20%
  - % pulmonary 80%
  - % bacteriologically confirmedººº 48%
  - % children aged 0–14 years 13%
  - % women 42%
  - % men 45%
- Patients with known HIV status who are HIV-positive 636 <1%
  - on antiretroviral therapy 417 66%

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 64% (48–90)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 8% (5–11)

Notified cases by age group and sex, 2018

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
  - New cases 45%
  - Previously treated cases 79%
Laboratory-confirmed cases*
  MDR/RR-TB: 3 824, XDR-TB: 95
Patients started on treatment**
  MDR/RR-TB: 3 106, XDR-TB: 71
MDR/RR-TB cases tested for resistance to second-line drugs 2 893

Treatment success rate and cohort size

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged <5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 5.7% (5.2–6.3)

TB financing, 2019
- National TB budget (US$ millions) 135
- Funding source: 3% domestic, 31% international, 66% unfunded

Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº Calculated for pulmonary cases only
ººº Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-26 Data: www.who.int/tb/data